Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain
The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A clinical study compared efficacy and safety of depot medroxyprogesterone acetate (DMPA) with leuprolide for endometriosis-associated pain. METHODS: This multicentre, 18 month, evaluator-blinded, comparator-controlled trial randomized 300 women with laparoscopically diagnosed endometriosis to 6 month treatment with subcutaneous injection of 104 mg/0.65 ml DMPA (DMPA-SC 104) every 3 months or leuprolide (3.75 mg monthly or 11.25 mg every 3 months), with 12 months post-treatment follow-up. Endpoints included patient response to treatment in five signs/symptoms (dysmenorrhoea, dyspareunia, pelvic pain, pelvic tenderness, induration) and changes in bone mineral density (BMD) and productivity at 6 and 18 months. RESULTS: DMPA-SC 104 and leuprolide produced equivalent (P < 0.02) reductions in at least four pain categories and significant (P < 0.001) improvements in composite score at months 6 and 18. At month 6, reductions in total hip and lumbar spine BMD were significantly less (P < 0.001) with DMPA-SC 104 versus leuprolide. BMD returned to pre-treatment levels 12 months post-treatment in the DMPA-SC 104 but not the leuprolide group. Total productivity also significantly (P < or = 0.05) improved in both groups at 6 and 18 months. CONCLUSIONS: DMPA-SC 104 reduces endometriosis-associated pain as effectively as leuprolide and improves productivity with significantly less BMD decline.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MPA appeared to be more effective than placebo [214] and as effective as danazol [215] and GnRH-agonists [216, 217] in reducing endometriosis-related pain.”
From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [216]
In the citing paper
“Depot medroxyprogesterone acetate (MPA; 104 mg, subcutaneous injection, every 3 months) has demonstrated an efficacy equivalent to LA, but long-term use of depot MPA preparations is shown to impact adversely on bone mineral density (BMD), while the delay in resumption of ovulation that may follow discontinuation of this therapy is a contraindication to use in women wishing to conceive in the near”
From Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial (2010) · cites this paper as Crosignani et al., 2006
In the citing paper
“Irregular uterine bleeding is a known adverse effect of treatment with progestins, including depot preparations of MPA, which have been compared in trials against LA (Vercellini et al., 2003;Crosignani et al., 2006;Schlaff et al., 2006).”
From Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial (2010) · cites this paper as Crosignani et al., 2006
In the citing paper
“In both studies DMPA-SC was statistically equivalent to GnRHa in reducing pain symptoms after 12 months' follow-up.”
From Oral and depot progestin therapy for endometriosis: towards a personalized medicine (2017) · cites this paper as [50]
In the citing paper
“Patients in the DMPA-SC group showed significantly less BMD loss than did leuprolide patients at month 6.”
From Oral and depot progestin therapy for endometriosis: towards a personalized medicine (2017) · cites this paper as [50]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Eskenazi, B., & Warner, M. L. (1997) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(05)70302-8 · Cited by 1,617
ESHRE guideline for the diagnosis and treatment of endometriosis
Kennedy, S., Bergqvist, A., Chapron, C., D’Hooghe, T., Dunselman, G., Greb, R., Hummelshoj, L., Prentice, A., & Saridogan, E. (2005) · Human Reproduction · doi:10.1093/humrep/dei135 · Cited by 1,584
Self-citationSutton, C. J. G., Ewen, S. P., Whitelaw, N., & Haines, P. (1994) · Fertility and Sterility · doi:10.1016/s0015-0282(16)56990-8 · Cited by 525
KUPPERMAN, H. S., BLATT, M. H. G., WIESBADER, H., & FILLER, W. (1953) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-13-6-688 · Cited by 478
Vercellini, P., Frontino, G., De Giorgi, O., Pietropaolo, G., Pasin, R., & Crosignani, P. G. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)00794-5 · Cited by 289
Self-citationDlugi, A. M., Miller, J. D., & Knittle, J. (1990) · Fertility and Sterility · doi:10.1016/s0015-0282(16)53755-8 · Cited by 279
Epidemiology of endometriosis-associated infertility.
Wheeler, J. M. (1989) · PubMed · Cited by 270
Treatment of severe postmenopausal endometriosis with an aromatase inhibitor
Takayama, K., Zeitoun, K., Gunby, R. T., Sasano, H., Carr, B. R., & Bulun, S. E. (1998) · Fertility and Sterility · doi:10.1016/s0015-0282(98)00022-3 · Cited by 270
Cited by
Clinical Management of Endometriosis
Falcone, T., & Flyckt, R. (2018) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002469 · Cited by 569
Consensus on current management of endometriosis
Johnson, N. P., Hummelshoj, L., for the World Endometriosis Society Montpellier Consortium, Abrao, M. S., Adamson, G. D., Allaire, C., Amelung, V., Andersson, E., Becker, C., Birna Árdal, K. B., et al. (2013) · Human Reproduction · doi:10.1093/humrep/det050 · Cited by 558
Progesterone and Estrogen Signaling in the Endometrium: What Goes Wrong in Endometriosis?
Marquardt, R. M., Kim, T. H., Shin, J.-H., & Jeong, J.-W. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20153822 · Cited by 491
Strowitzki, T., Marr, J., Gerlinger, C., Faustmann, T., & Seitz, C. (2010) · Human Reproduction · doi:10.1093/humrep/dep469 · Cited by 381
Systematic review of endometriosis pain assessment: how to choose a scale?
Bourdel, N., Alves, J., Pickering, G., Ramilo, I., Roman, H., & Canis, M. (2015) · Human Reproduction Update · doi:10.1093/humupd/dmu046 · Cited by 372
Metadata
- Authors
- Crosignani, P. G., Luciano, A., Ray, A., & Bergqvist, A.
- Affiliations
- University of Milan (IT)
- University of Connecticut (US)
- Pfizer (United States) (US)
- Danderyds sjukhus (SE)
- Corresponding author
- Crosignani, P.G.
- ORCID
- Venue
- Human Reproduction
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-09-21
- Volume
- 21
- Issue
- 1
- Pages
- 248-256
- ISSN
- 0268-1161 (ISSN-L)
- 1460-2350
- OpenAlex
- W2169590550
- Cited by
- 179
- References
- 42
- Citations by year
- 2026: 8 · 2025: 5 · 2024: 5 · 2023: 7 · 2022: 4 · 2021: 6 · 2020: 8 · 2019: 9 · 2018: 14 · 2017: 10 · 2016: 6 · 2015: 11 · 2014: 7 · 2013: 10 · 2012: 10
- FWCI
- 5.96
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Human Reproduction (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
- Keywords
- endometriosis, endometriosis-associated pain, depot medroxyprogesterone acetate, leuprolide, subcutaneous injection, dysmenorrhea, dyspareunia, pelvic pain, bone mineral density, bone loss, labor productivity, GnRH agonist, GnRH antagonist
- MeSH terms
- Administration, Cutaneous, Adult, Contraceptive Agents, Female, Endometriosis, Female, Fertility Agents, Female, Hip, Humans, Lumbar Vertebrae, Quality of Life, Radiography, Uterine Diseases, Bone Density, Leuprolide, Treatment Outcome, Medroxyprogesterone Acetate, Pelvic Pain, Antineoplastic Agents, Hormonal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. https://app.cochat.ai/papers/10.1093/humrep/dei290
- The paper
- Crosignani, P. G., Luciano, A., Ray, A., & Bergqvist, A. (2006). Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Human Reproduction. https://doi.org/10.1093/humrep/dei290
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.